InSphero

🎥 Peer-reviewed Publication by InSphero & FDA’s NCTR | Insights from the Authors In this interview, the first author, Lola Fäs, and the corresponding author, Dr. Bruno Filippi from our Liver Safety team share exclusive insights from the recent publication in Toxicological Sciences. 📄 What’s it about? In this video, our experts discuss the landmark research conducted by InSphero and scientists from the FDA’s National Center for Toxicological Research. They dive into the groundbreaking use of 3D liver microtissues in detecting drug-induced liver injury (#DILI) and share key findings, including: 🟢 Testing of 152 FDA-approved drugs with our 3D liver microtissues, which accurately predict #DILI, one of the leading causes of drug development discontinuation 🟢 How the technology correctly identified 90% of safe drugs and 80% of the withdrawn compounds. 🟢 The scalability of our Akura™ 384-well microplate system for early drug testing. 🎬 Watch the full interview to learn more about how InSphero’s technology drives safer, more efficient drug development. Read the full publication via the link in comments 👇 Jan Lichtenberg Madhu Lal Nag, MBS PhD Paul Edgard Clémençon Wolfgang Moritz Filip Henzler Rositsa Hadzhipetrova Arumugham (Ragoo) Raghunathan Arnab China, PhD Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Anna Borgström Tina Žel Tong Weida, minjun chen, Friederike Wenz, Monika Tu, Katarzyna Sanchez, Natalia Zapiórkowska-Blumer, Hajnalka Varga, Karolina Kaczmarska, Maria Vittoria Colombo #DrugDevelopment #Toxicology #LiverToxicity #3DCellCulture #InSphero #FDA #PharmaInnovation

In the world of developing complex in vitro models, understanding the context of use is absolutely essential. Imagine trying to create a single assay solution that suits every possible application—much like putting shrimp, sushi, and chicken wings on an ice cream cone. It doesn’t taste good and ultimately serves no one well. Take liver models as an example, an area where we are exceptionally good at InSphero . Different contexts of use—such as flagging safety concerns, studying mechanistic toxicology, or exploring patient diversity—require distinct features and qualifications. A 3D assays designed primarily for early safety screening focuses on quickly identifying potential toxicity, while one built for mechanistic toxicology needs to delve into the biological pathways and cellular responses that drive toxicity. And if the goal is to understand patient diversity, the model must incorporate genetic variability and factors reflecting different populations. Trying to combine all these requirements into a single model risks diluting the effectiveness of each, much like mixing flavors that do not blend. Reproducibility is another critical consideration. When a model attempts to address too many purposes, variability increases, and consistency suffers, making it challenging to generate reliable, actionable data. In turn, this impacts turnaround time and inflates costs, as users have to work with a solution that is overloaded and not cost efficient. The takeaway? Just as we wouldn’t serve a culinary experiment gone wrong to your guests, we shouldn’t deploy an all-encompassing but poorly optimized in vitro model or platform to the scientific community. Understanding the context of use ensures we deliver models that are fit-for-purpose, maximizing accuracy, efficiency, and relevance in real-world applications. Let’s focus on the right ingredients for each scenario, ensuring our models serve a specific, well-understood purpose—and truly deliver the taste of excellence. 🍧🍤🍣🍗 Paul Edgard Clémençon Madhu Lal Nag, MBS PhD Filip Henzler Arumugham (Ragoo) Raghunathan Bruno Filippi Arnab China, Ph.D. Sue Grepper, PhD Bärbel Ulmer Christine Schwenk Rizwan Chaudhrey #3Dcellculture #organonchips #invitrotoxicology #NAMs #drugsafety

Excited about ACT 2024! 🎉 Join us at the American College of Toxicology (ACT) 2024 Annual Meeting in Austin, Texas, from November 17-20! Visit us at Booth 📍 #503 to explore our 3D InSight™ Liver Safety platform for drug-induced liver injury (DILI) assessment. Have you seen our latest peer-reviewed paper with FDA’s NCTR on DILI? Want to hear more directly from the experts? Join our Exhibitor-Hosted Session, where Dr. Bruno Filippi, Vice President of Liver Safety, will present key findings from our study published in Toxicological Sciences: “Physiological Liver Microtissue 384-Well Microplate System for Preclinical Hepatotoxicity Assessment of Therapeutic Small Molecule Drugs” When and where? 📅 Tuesday, November 19, 2024 🕖 12:00 - 12:55 PM 📍 Level 2, Room 204   This study underscores the unmatched predictive power of our 3D human liver technology, helping reduce late-stage drug failures, lower R&D costs, and accelerate the development of safer drugs. Don’t miss the chance to meet our experts and learn how 3D InSight™ can elevate your research. Check the link in the comments for more info. See you in Austin! 🌵 #ACT2024 #LiverSafety #3DInVitro #Toxicology #DILI #Innovation #DrugDevelopment Maria Vittoria Colombo, Paul Edgard Clémençon, Arumugham (Ragoo) Raghunathan, Anna Borgström, Lola Fäs, Katarzyna Sanchez, Monika Tu, Karolina Kaczmarska, Hajnalka Varga, Bärbel Ulmer, Arnab China, Ph.D., Sue Grepper, PhD, Christine Schwenk, Rositsa Hadzhipetrova, Tina Žel

✈️ Bruges, here we come for IDS 2024! ✈️ From November 4th to 8th, we’ll be at the center of diabetes and immunology innovation at The Immunology of Diabetes Congress (IDS) 2024! IDS gathers leading scientists, clinicians, and industry experts to share insights on the immune system’s role in diabetes, moving the field forward in prevention, treatment, and ultimately a cure. Don’t miss the chance to connect with our team and learn how our 3D InSight™ Islet Biology Platform provides a complete end-to-end solution for studying islet function, β-cell regeneration, and β-cell preservation. We’re excited to showcase how this platform advances research in physiologically relevant disease models. 🗓️ To schedule the meeting with us visit our website. The link is in the comments. 👇 👋See you in Bruges! #IDS2024 #DiabetesResearch #Immunology #Innovation #3DInVitro #Diabetes #TheModelofExcellence ™ Burcak Yesildag, Alexandra Title, Sayro Jawurek, Ben Kodiyan, Felix Forschler, Lynn Scherpe, Christine Schwenk, Bärbel Ulmer, Sue Grepper, PhD, Arnab China, Ph.D., Arumugham (Ragoo) Raghunathan, Paul Edgard Clémençon, Rositsa Hadzhipetrova, Tina Žel

✈️ On Our Way to NESOT! ✈️ Our Senior Director of Business Development, EC, Dr. Arumugham (Ragoo) Raghunathan, will be attending NESOT 2024 on October 25 at the Pfizer site in Cambridge, MS, and we’re excited to be a Bronze sponsor this year! 🥉 The theme, "Toxicology in the ‘Omics Era," is a perfect fit for our innovative solutions in toxicology. 🧬 Stop by the InSphero booth or catch Dr. Raghunathan’s poster presentation 🎤, "On the Relevance of Human Liver Microtissues for the Detection of Hepatotoxic Drugs Early in the Drug Development Process," from 12:00 - 1:00 PM. Don’t miss the chance to connect with him and learn how our technology can elevate your research to the next level! 🔬✨ Can’t make it to NESOT? No worries! Meet us at these upcoming events:   📍American College of Toxicology (ACT) 45th Annual Meeting 2024| November 17-20 in Austin, Texas | Booth #503  📍 Society of Toxicology (SOT) 2025 | March 16-20 in Orlando, Florida | Booth #1211 We’d love to connect—reach out and schedule a meeting with our team today! 🗓️🤝 Check out our activities at the ACT Annual Meeting on our website. The link is in the comments. 👇    #NESOT2024 #Toxicology #LiverSafety #DILI #Innovation #Biotech #Networking #DrugDevelopment #ACT2024 #SOT2025 #TheModelofExcellence ™ Bruno Filippi, Anna Borgström, Maria Vittoria Colombo, Lola Fäs, Katarzyna Sanchez, Monika Tu, Karolina Kaczmarska, Hajnalka Varga, Bärbel Ulmer, Arnab China, Ph.D., Sue Grepper, PhD, Christine Schwenk, Paul Edgard Clémençon, Rositsa Hadzhipetrova, Tina Žel

🌟 Off to Rome! 🌟 Our Business Development Director, Dr. Bärbel Ulmer will attend the European Society of Gene and Cell Therapy (ESGCT) Congress 2024 in Rome from October 22 to 25! 🇮🇹 Dr. Ulmer will be presenting a poster titled: "AAV Capsid Variant Screen for Diabetes Research: Building a High-Throughput Compatible Methodology for Modification of Human Islet Gene Expression" 📅 Date: Tuesday, October 22 🕖 Time: 19:30-21:00 📍 Poster Number: P0357 Developed in collaboration with Boehringer Ingelheim Pharma, this poster showcases a scalable platform for AAV-mediated gene modification in human islets, achieving impressive transduction efficiency with clear differences between capsis. Key findings include: • AAV2.7m8, AAV6 and KPI achieved the highest transduction efficiency while AAV5, AAV8 and AAV9 showed lower percentages of transduced cells. • Most capsids used preserve viability and function (glucose-stimulated insulin secretion) These results offer promising insights for more effective diabetes research and therapeutic development! Don't miss this opportunity to engage with cutting-edge science at ESGCT 2024! #ESGCT2024 #GeneTherapy #CellTherapy #DiabetesResearch #AAV #Collaboration #Innovation #Rome #Biotechnology #ScientificResearch #PosterPresentation #Diabetes #BoehringerIngelheim Burcak Yesildag, Alexandra Title, Sayro Jawurek, Ben Kodiyan, Felix Forschler, Lynn Scherpe, Christine Schwenk, Sue Grepper, PhD, Arumugham (Ragoo) Raghunathan, Arnab China, PhD, Rositsa Hadzhipetrova, Tina Žel

At InSphero, we drink water from glass bottles 💧, and a recent study using our assay-ready liver microtissues reinforces why it’s a smart choice to avoid #microplastics: 💡 Microplastic-triggered size-and concentration-dependent #inflammation (e.g. IL6 secretion, see graph below) and accumulation, visible as white dots, in Kupffer cells, our liver's resident macrophages (look at red boxes in histology below). 🔔 Fridays are for reflecting on the week’s progress, and exploring such exciting science reminds us why we’re passionate about what we do! 🚀 We’re proud to share this post, curated by our Director of Business Development, Dr. Bärbel Ulmer, and excited to keep pushing forward with these critical findings. Access the paper via the link in the comments 👇 Paul Edgard Clémençon Christine Schwenk Sue Grepper, PhD Arumugham (Ragoo) Raghunathan Arnab China, PhD Tina Žel Rositsa Hadzhipetrova Wolfgang Moritz Madhu Lal Nag, MBS PhD Bruno Filippi Francisco Verdeguer #LiverSafety #Research #Publication

🌟 Austin, here we come! 🌟 We’ll be attending the American College of Toxicology (ACT) 45th Annual Meeting 2024 from November 17-20 in Austin, Texas! 🎉 Be sure to stop by Booth #503 to explore our 3D InSight™ Liver Safety platform –a verified, practical & physiological 3D In Vitro Solution for DILI Assessment. Discover how we’re advancing toxicology research with: 🔬 Predictive Tox 🔍 Investigative Tox 🚀 Translational Tox Our experts will be on hand to share insights and answer your questions: - Dr. Bruno Filippi, Vice President, Liver Safety - Dr. Maria Vittoria Colombo, Scientist/Product Coordinator, Liver Safety - Paul Edgard Clémençon, MBA, Chief Business Officer - Dr. Arumugham (Ragoo) Raghunathan, Senior Director, Business Development, EC Check out our activities at the Annual meeting on our website. Link is in the comments. 👇 Don’t miss this opportunity to connect with our team and learn how 3D InSight™ can elevate your research! See you in Austin! 🌵 #Toxicology #ACT2024 #LiverSafety #3DInVitro #PredictiveTox #InvestigativeTox #TranslationalTox #AustinTexas #DILI #Innovation #AnnualMeeting #TheModelofExcellence™ Anna Borgström, Lola Fäs, Katarzyna Sanchez, Monika Tu, Karolina Kaczmarska, Hajnalka Varga, Bärbel Ulmer, Arnab China, PhD, Sue Grepper, PhD, Christine Schwenk, Rositsa Hadzhipetrova, Tina Žel

🌟 Thank You for Making the Swiss Pavilion at BioJapan 2024 a Success! 🌟 Last Friday marked the conclusion of BioJapan 2024. We were thrilled to see such a fantastic turnout at the Swiss Pavilion, with a diverse and engaged audience from across Asia. The atmosphere was electric with lively business discussions, reflecting a remarkable 115% increase in visitors and partnering meetings compared to last year. This surge in interest underscores the growing importance of platforms like BioJapan in fostering international collaborations. A special thank you to all the visitors who stopped by the Swiss Pavilion to connect with our exhibitors. To our Swiss exhibitors, thank you for your dedication and hard work. Your enthusiasm and insights are invaluable in driving innovation forward. The bustling activity at your booths was a testament to your commitment to forging new partnerships and opportunities. We look forward to continuing this momentum and building on the connections made at BioJapan 2024. Here's to continued success and future collaborations! #BioJapan2024 #SwissPavilion #Innovation #GlobalCollaboration #ThankYou #switzerland #japan CARBOGEN AMCIS Bachem Consulate of Switzerland, Swissnex in Japan PULSE - Modular Life Science Center Perseo pharma AG InSphero Global Antibiotic R&D Partnership (GARDP) Drugs for Neglected Diseases initiative - DNDi Lonza CSEM Switzerland Innovation Switzerland Global Enterprise Invest in Switzerland

🚨 New Peer-reviewed Publication Alert 🚨   We’re thrilled to announce the publication of our landmark study in Toxicological Sciences, conducted with scientists from the U.S. FDA’s National Center for Toxicological Research (#NCTR). This study represents the largest benchmarking of liver toxicity testing using our 3D InSight™ Human Liver #Microtissues.   📊 Key Highlights: ✅ The study tested 152 FDA-approved drugs and demonstrated that 3D liver microtissues accurately predict #DILI, one of the leading causes of drug development discontinuation ✅ The applied 3D in vitro liver model correctly flagged 80% of the withdrawn drugs due to liver toxicity, while it accurately classified 89% of the safe drugs. For liver-toxic drugs targeting the nervous system, the liver microtissues achieved a 90% success rate. ✅ The use of #384-well Akura™ Spheroid Microplates enables high-throughput screening, making the system #scalable and ideal for large-scale hepatotoxicity assessment applications. ✅ This study not only marks a significant advancement in early liver toxicity detection, but it also highlights the unmatched predictive power of the 3D liver microtissue technology. ✅#InSphero’s Liver Safety Platform's showcased promising path to reducing late-stage ✖️ drug failures and has the potential to ✅ save millions in R&D costs and accelerate the development of safer drugs. 🚀 Dr. Jan Lichtenberg, CEO and Co-founder of InSphero: “Our work with the FDA’s NCTR is a breakthrough in liver toxicology research and sets a new industry standard.”   👏 Congratulations to all authors on this scientific important milestone - Lola Fäs, Tong Weida, minjun chen, Friederike Wenz, Monika Tu, Katarzyna Sanchez, Natalia Zapiórkowska-Blumer, Hajnalka Varga, Karolina Kaczmarska, Maria Vittoria Colombo, Bruno Filippi 👏   Read the full press release and access the paper via the link in comments 👇 Jan Lichtenberg Madhu Lal Nag, MBS PhD Paul Edgard Clémençon Wolfgang Moritz Filip Henzler David Fluri Francisco Verdeguer Burcak Yesildag Laure-Anne Ligeon Olivier Frey Dr. Henriette Schneider Marion Bavand Rositsa Hadzhipetrova Stina Näslund Arumugham (Ragoo) Raghunathan Arnab China, PhD Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Anna Borgström Tina Žel   #DrugDevelopment #Toxicology #LiverToxicity #3DCellCulture #FDA #InSphero #PharmaInnovation